Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Cancer

NCT05296772 is registered in ClinicalTrials.gov with Anwita Biosciences as lead sponsor.

NCT NCT05296772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05296772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of JS014, a Recombinant Fusion Protein of Interleukin-21 and Humanized Anti-human Serum Albumin VHH Antibody as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Cancer
Lead sponsor
Anwita Biosciences
Phase
Phase 1
Overall status
Unknown status
Start date
February 28, 2022
Completion date
January 31, 2025
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, neoplasm malignant, neoplasm, experimental, solid tumor, adult